12:00 AM
May 07, 2007
 |  BioCentury  |  Finance

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 5/4 cls
Aeterna Zentaris (TSX:AEZ; AEZS) Dundee David Martin Price target Market outperform 3% $3.96
Martin lowered his target to C$6.50 from C$7 after AEZ said enrollment in a 160-patient Phase II trial of perifosine in combination with radiation to treat non-small cell lung cancer (NSCLC) is taking longer than expected. The company had hoped to complete enrollment by the end of 2Q. Perifosine is an alkylphosphocholine compound that modulates Akt and other signal transduction pathways.
Anadys (ANDS) Piper Jaffray Edward Tenthoff Price target Market outperform -2% $4.05
Tenthoff lowered his target to $5 from $7 after ANDS said it and partner LG Life Sciences have not yet agreed on a development plan for HBV compound ANA380 and that a Phase IIb trial of the nucleotide analog viral polymerase inhibitor is unlikely to begin this year.
Antisoma (LSE:ASM) Needham Mark Monane New Buy 4% 55p
Monane set an 82p target. He said a deal with Novartis (NVS; SWX:NOVN) for ASM's AS1404 validates the potential of the vascular disrupting agent, which has completed Phase II trials in lung cancer and is in Phase II testing for prostate and ovarian cancer (see BioCentury, April 23). He expects NVS to start Phase III trials in NSCLC in early 2008.

Read the full 1241 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >